Form 4 for DGX Quest Diagnostics
Accepted 2025-11-28 00:00:00 ET · period of report 2025-11-25 · accession 0001022079-25-000233 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-28 | 2025-11-25 | DGX | Davis J. E. | CEO, Pres, Dir | S - Sale+OE | $192.22 | -55.1K | 125.2K | -31% | -$10.59M |
| D | 2025-11-28 | 2025-11-25 | DGX | Davis J. E. | CEO, Pres, Dir | M - OptEx | $95.80 | +55.1K | 175.6K | +46% | +$5.28M |
| D | 2025-11-28 | 2025-11-25 | DGX | Davis J. E. | CEO, Pres, Dir | M - OptEx | $95.80 | -55.1K | 0 | -100% | -$5.28M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-25 | S | D | 9,342 | $191.59 | 166,231 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $190.810 to $191.805. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2025-11-25 | M | A | 55,093 | $95.80 | 175,573 | D | — | — | |
| 3 | Common | Common Stock | 2025-11-25 | S | D | 4,747 | $192.97 | 120,480 | D | — | — | (F4) This transaction was executed in multiple trades at prices ranging from $192.820 to $193.310. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Common | Common Stock | 2025-11-25 | S | D | 41,004 | $192.27 | 125,227 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $191.820 to $192.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 5 | Derivative | Non-Qualifed Stock Option (right to buy) | 2025-11-25 | M | D | 55,093 | $95.80 | 0 | D | $95.80 · — to 2027-02-21 | 55,093 Common Stock | (F5) The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. |